[The synthetic peptide preparation dalargin in the treatment of peptic ulcer].
The paper is concerned with the results of clinical assessment of a new peptide drug dalargin in therapy of duodenal peptic ulcer. Assessment of the efficacy of dalargin was compared to that of tagamet and placebo using double "blind" control. A total of 180 males with exacerbation of duodenal ulcer were examined, of them 90 received dalargin only, 70 received tagamet and 20 persons participated in an experiment based on a method of double "blind" control. An average period of duodenal ulcer healing in the patients on dalargin therapy was 21.4 +/- 1.2 days, and by the 28th day complete cicatrization was observed in 87.5% of the patients. In tagamet therapy an average period of cicatrization was 23.7 +/- 1.8 days, by the 28th day ulcer healing was observed in 87.3%. With placebo ulcer healing by the 4th week was observed in 30% of the examinees, in dalargin therapy in 80%. A conclusion was made of high efficacy of dalargin for therapy of peptic ulcer.
D000293:Adolescent; D000328:Adult; D002927:Cimetidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged
D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; D002927:Cimetidine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
Sinteticheskiĭ peptidnyĭ preparat dalargin v lechenii iazvennoĭ bolezni.